appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Eric Ng

Antibody-drug conjugates (ADC), a fast-growing next-generation cancer treatment, have become an investment hotspot due to its potential to become mainstream globally, according to biopharmaceutical industry insiders.
To achieve sustainable growth and maximise revenue potential, companies should pursue differentiated product development and a global clinical strategy, according to Duality Biotherapeutics, which organised a biotech forum in Shanghai last week.
The Shanghai-based company – which raised HK$1.64 billion (US$211 million) from its Hong Kong initial public offering (IPO) in April – has avoided focusing only on the most popular market segments to avoid overcrowding, according to Mu Hua, the global chief medical officer.
“We have a differentiated strategy focused on carefully selected disease categories that maximise the commercial potential,” he said. “Many Chinese ADC developers focus on lung cancers, whereas we have chosen to spend significant resources on a certain type of prostate cancer based on our research, as well as market potential and competition.”

He said that a company could be more financially successful by being the first to launch a novel ADC drug for a difficult-to-treat cancer like castration-resistant prostate cancer than a rival that was first to market with a less differentiated drug for another cancer.
Duality Biotherapeutics was among a rising number of firms focusing on ADCs, whose sales were forecast to grow by around 30 per cent a year to US$115 billion in 2032 from US$10.4 billion in 2023, according to Frost & Sullivan, which was hired by the company to conduct market analysis for its IPO.
ADC, a novel method on how oncology drugs are constituted and delivered, was gaining traction as next-generation therapies, said Lu Shun, a professor at Shanghai Chest Hospital, affiliated to Shanghai’s Jiao Tong University.
“This year, bi-specific ADC has become a hotspot for lung cancer therapy development globally, following over two decades of targeted therapy and immunotherapy development,” Lu told the forum.
Unmet needs remained big despite significant improvement in treatments in recent years, he added.
The average five-year post-diagnosis survival rate for lung cancer patients was 29 per cent in China, compared with 81 per cent for breast cancer, 71 per cent for prostate cancer and 56 per cent for colon cancer, according to data from the National Cancer Centre published last year.
“But that will change, as we have new ways to treat [various cancers], with the emergence of bi-specific antibodies and ADCs,” Lu said.
An ADC is a kind of “guided missile-like” chemotherapy for achieving precise action that lasts longer and with fewer side effects. It uses an antibody to find and bind to a specific protein, or biomarker, on the surface of cancer cells.
After getting absorbed into the cells, a “link” bridging the antibody and a chemotherapy drug carried by the ADC releases the drug inside the cancer cells to kill them. Bi-specific antibodies can bind to two different proteins on cancer cells.
Since most cancer patients over time develop resistance to immunotherapies, novel treatments like ADCs were needed, Guo Ye, a professor at Affiliated Oriental Hospital of Shanghai’s Tongji University, told the forum.
ADCs have broad potential for a variety of cancers, he noted, adding that their efficacy could be improved further by combining with targeted therapies like tyrosine kinase inhibitors – drugs that block enzymes responsible for cancer cells’ growth.
A late-stage study showed that this combination could overcome drug-resistant lung cancers.
“I am optimistic that ADC-bi-specific immunotherapy drugs can one day replace most existing oncology first-line treatments,” Guo said.
While the world’s first ADC was approved in 2000, 11 of the 16 ADCs on the market were approved after 2019, with five achieving over US$1 billion in sales annually, according to Duality Biotherapeutics.
Some 190 ADCs were under active clinical evaluation worldwide, according to a paper by researchers at Guangzhou’s Sun Yat‐sen University published in the Cancer Communications journal in December 2023.
In China, 63 per cent of the newly developed ADCs were concentrated on the top 10 targets, compared with 48 per cent globally, according to the study.


Alibaba open-sources medical AI model that can detect cancer and nearly 150 conditions

How China plans to ‘firmly rank at the global forefront’ with 25% of first-in-class drugs

ByteDance spin-off Anew Labs raises US$290m as AI drug developers enjoy fundraising boom

GSK licenses Chinese firm’s cancer drug in US$750 million deal

Biomedicine: Companies

China biotech forum bills antibody cancer drugs as next-generation treatment

Antibody drug conjugates  are targeted medicines that deliver chemotherapy agents to cancer cells. Photo: Shutterstock

Mu Hua, the global chief medical officer at Duality Biotherapeutics. Photo: Handout

China’s Hengrui gets boost from fifth drug-licensing deal of year, adds India partner

A worker checks a machine at Hengrui Biomedical Industrial Park in Lianyungang, in East China’s Jiangsu province, on December 13, 2021. Photo: Future Publishing via Getty Images

Glenmark will pay US$18 million up front plus up to US$1.1 billion in payments based on certain regulatory and commercial performance targets. Photo: Handout

China’s Akeso, dubbed biotech’s DeepSeek, gets share boost on cancer-drug trial data

Trial showed “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said. Photo: Shutterstock

Akeso founder and CEO Michelle Xia. Photo: Handout

Chinese biotech firm secures US$6 billion Pfizer deal for cancer drug

3SBio was established in 1993 with an initial focus on interferons, a type of protein that helps the immune system. Photo: Handout

China’s biotech renaissance: rising drug-creation prowess attracts global notice

 Illustration:  Henry Wong

A view of Akeso’s global innovation centre in Shanghai. Photo: Handout

Chinese biotech’s mega drug-licensing deals with multinationals surge on cost savings

Good mid-stage drug candidates from China at prices far below those in the US market are driving an increase in licensing deals, analysts say. Photo: Shutterstock

Sun Chuan, Shanghai-based managing partner at international law firm Morrison Foerster. Photo: Handout

Business

News

China Future Tech

Biomedicine

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies


Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.


China biotech forum bills antibody cancer drugs as next-generation treatment

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies